Published in Drug Week, July 28th, 2006
"Smallpox is a devastating bioterrorism threat and vaccination is not an option for more than 40 million Americans with compromised immune systems," said Dr. George Painter, Chimerix president and CEO. "Using our platform technology, we have developed CMX001, an orally available drug candidate. We expect CMX001 to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.